Get started
Author

Marc Yale

Observed names: M Yale, M. Yale, M.L. Yale, Marc L. Yale, Yale, Marc
ORCID: 0009-0006-6722-3569
Observed ORCID: 0009-0006-6722-3569
OpenAlex ID: A5113853573
Expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic
2020 · M. Kasperkiewicz, E. Schmidt, et al. · Journal of the European Academy of Dermatology and Venereology · 59
PDF
Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic
2021 · M. Kasperkiewicz, E. Schmidt, et al. · Journal of the European Academy of Dermatology and Venereology · 33
PDF
Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference
2018 · Jinmin Lee, Victoria P. Werth, et al. · Frontiers in Medicine · 27
PDF
Unmet Needs in Pemphigoid Diseases: An International Survey Amongst Patients, Clinicians and Researchers
2018 · A Lamberts, M Yale, et al. · Acta Dermato Venereologica · 23
PDF
Psychosocial burden of autoimmune blistering diseases: A comprehensive survey study
2024 · Marney A. White, Victoria M. Hoffman, et al. · Journal of the European Academy of Dermatology and Venereology · 16
PDF
COVID ‐19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross‐sectional study of the International Pemphigus and Pemphigoid Foundation
2021 · M. Kasperkiewicz, R. Strong, et al. · British Journal of Dermatology · 13
Assessing the risk factors for anxiety, depression and post‐traumatic stress disorder through the International Pemphigus and Pemphigoid Foundation
2021 · P.M. Patel, V.A. Jones, et al. · Journal of the European Academy of Dermatology and Venereology · 11
COVID‐19 pandemic and autoimmune bullous diseases: a cross‐sectional study of the International Pemphigus and Pemphigoid Foundation
2021 · M. Kasperkiewicz, M. Yale, et al. · Journal of the European Academy of Dermatology and Venereology · 9
PDF
Gastrointestinal symptoms, gastrointestinal bleeding and the role of diet in patients with autoimmune blistering disease: a survey of the International Pemphigus and Pemphigoid Foundation
2019 · D. Kneiber, E.H. Kowalski, et al. · Journal of the European Academy of Dermatology and Venereology · 9
The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid
2023 · Marc Yale, Patrick Dunn, et al. · Journal of Investigative Dermatology · 7
PDF
Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions
2025 · Marjolein A J Hiel, Eva W H Korte, et al. · British Journal of Dermatology · 6
PDF
Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece
2024 · Meropi Karakioulaki, Patrick Dunn, et al. · JID Innovations · 5
PDF
Safety of the COVID ‐19 vaccine booster in patients with immunobullous diseases: A cross‐sectional study of the International Pemphigus and Pemphigoid Foundation
2022 · Michael Kasperkiewicz, Rebecca Strong, et al. · Journal of the European Academy of Dermatology and Venereology · 4
Bullous pemphigoid outcome measurement: a scoping review of outcome heterogeneity and trends in clinical research of treatments
2025 · Marjolein A J Hiel, Billal Tedbirt, et al. · British Journal of Dermatology · 2
PDF
The impact of health insurance delays on biologic therapy access in autoimmune bullous disease: a single-center retrospective analysis
2025 · Paige E. Adams, Elise K. Brunsgaard, et al. · Archives of Dermatological Research · 2
A cross‐sectional study of dermatologists' attitudes towards COVID ‐19 vaccination in patients with immunobullous diseases
2022 · Michael Kasperkiewicz, Rebecca Strong, et al. · Journal of the European Academy of Dermatology and Venereology · 2
Adaptation and Validation of the Fear of Blistering Disease Recurrence Inventory
2025 · Marney A. White, Sébastien Simard, et al. · Dermatology · 1
Patient Experiences of Bullous Pemphigoid: Symptoms and Health-Related Quality of Life Impacts
2025 · Calvin N. Ho, Lila Bahadori, et al. · Dermatology and Therapy · 1
PDF
Role of the International Pemphigus and Pemphigoid Foundation during the COVID ‐19 pandemic
2022 · M. Kasperkiewicz, R. Strong, et al. · Journal of the European Academy of Dermatology and Venereology · 1
Insurance-related barriers to biologic therapy for autoimmune blistering diseases: a survey of patients in the United States
2026 · Paige E. Adams, Elise K. Brunsgaard, et al. · Archives of Dermatological Research
International development of Investigator Global Assessment scores for pemphigus
2026 · Dédée F. Murrell, Darby Boucher, et al. · Journal of the European Academy of Dermatology and Venereology
The burden of insurance requirements on timely access to biologic therapy for patients with autoimmune blistering diseases: a survey of immunobullous experts in the United States
2025 · Paige E. Adams, Elise K. Brunsgaard, et al. · Archives of Dermatological Research
Mucous Membrane Pemphigoid Outcome Measurement in Clinical Research: A Scoping Review
2025 · Billal Tedbirt, Eva W. H. Korte, et al. · Clinical Drug Investigation
Navigating challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey
2025 · Eva W H Korte, Marjolein A J Hiel, et al. · British Journal of Dermatology
PDF
LB862 Psychosocial burden of autoimmune blistering diseases (AIBD): A comprehensive survey study
2024 · V.M. Hoffman, M. White, et al. · Journal of Investigative Dermatology
PDF
Works count: 30
Citation count: 231
H-index: 9
I10-index: 7
Year
Topic
Type